Andrew M. Intlekofer: Publications

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discovery. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud NR, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125-129.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Integrated DNA/RNA Targeted Genomic Profiling of Diffuse Large B Cell Lymphoma Using a Clinical Assay. Blood Cancer Journal. 2018 Jun 12;8(6):60.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Heiden MGV, Thompson CB, Levine RL. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. Journal of Clinical Investigation. 2018 Feb 1;128(2):789-804.

Pavlova NN, Hui S, Ghergurovich JM, Fan J, Intlekofer AM, White RM, Rabinowitz JD, Thompson CB, Zhang J. As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid. Cell Metabolism. 2018 Feb 6;27(2):428-438.e5.

Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer A, Meydan C, Qin T, Fall MP, Alonso A, Guzman ML, Valk PJ, Thompson CB, Levine RL, Elemento O, Delwel R, Melnick A, Figueroa ME. Epigenetic Identity in AML Depends on Disruption of Non-promoter Regulatory Elements and is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery. 2017 Apr 13. pii: CD-16-1032. doi: 10.1158/2159-8290.CD-16-1032.

Intlekofer AM, Wang B, Liu H, Shah H, Carmona-Fontaine C, Rustenburg AS, Salah S, Gunner MR, Chodera JD, Cross JR, Thompson CB. L-2-hydroxyglutarate production arises from non-canonical enzyme function at acidic pH. Nature Chemical Biology. 2017 May;13(5):494-500. doi: 10.1038/nchembio.2307.

Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer A, Nazir A, Stein E, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason C, Yen K, Thompson CB, Melnick A, Levine RL. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discovery. 2017 Feb 13. pii: CD-16-1049.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koester J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu S-C, Plana O, Montero J, Stevenson KE, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf N, LaCasce AS, Lees E, Li L, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli M, Ritz J, Brown M, Long H, Aster JC, Shipp M, Griffin JD, Weinstock DM. The Public Repository of Xenografts (PRoXe) enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016 Apr 11;29(4):574-86.

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Jun 16;127(24):3004-14.

Intlekofer AM, Dematteo RG, Venneti S, Finley LWS, Lu C, Judkins AR, Rustenburg AS, Grinaway, PB, Chodera JD, Cross JR, Thompson CB. Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metabolism. 2015 Aug 4; 22(2):304-11.

Highlighted in “Cancer metabolism: Two sides of a coin” by Grant Miura. Nature Chemical Biology. 2015 Aug 18; 11(9):632.
Highlighted in “A New Hydroxy Metabolite of 2-Oxoglutarate Regulates Metabolism in Hypoxia” by Adrian L. Harris. Cell Metabolism. 2015 Aug 4;22(2):198-200.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences. 2014 Dec 16;111(50):E5401-10.

Mancebo SE, Smith JR, Intlekofer AM, Zelenetz AD, Myskowski PL. Treatment Response of Cutaneous Mantle Cell Lymphoma to Ibrutinib and Radiotherapy. Clinical Lymphoma Myeloma Leukemia. 2014 Nov 18. pii:S2152-2650(14)00497-2.

Intlekofer AM, Younes A. Precision therapy for lymphoma—current state and future directions. Nature Reviews Clinical Oncology. 2014 Oct;11(10):585-96. Review.

Intlekofer AM, Younes A. From empiric to mechanism-based therapy for peripheral T cell lymphoma. International Journal of Hematology. 2014 Mar;99(3):249-62. Review.

Lu C, Venneti S, Akalin A, Fang F, Ward PS, DeMatteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram N, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. Induction of sarcomas by mutant IDH2. Genes & Development. 2013 Sep 15;27(18):1986-98.

Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Journal of Leukocyte Biology. 2013 Jul;94(1):25-39. Review.

Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O’Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK. A case of advanced gastric cancer. Gastrointestinal Cancer Research. 2012 Mar;5(2):59-63.

Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, Wherry EJ. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nature Immunology. 2011 May 29;12(7):663-71.

Kinjyo I, Gordon SM, Intlekofer AM, Dowdell K, Mooney EC, Caricchio R, Grupp SA, Teachey DT, Rao VK, Lindsten T, Reiner SL. Cutting edge: Lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. The Journal of Immunology. 2010 Dec 15;185(12):7151-5.

Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner SL. Cutting edge: The transcription factor eomesodermin enables CD8⁺ T cells to compete for the memory cell niche. The Journal of Immunology. 2010 Nov 1;185(9):4988-92.

Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ. A role for the transcriptional repressor Blimp-1 in CD8⁺ T cell exhaustion during chronic viral infection. Immunity. 2009 Aug 21; 31(2):1-12.

Yashiro-Ohtani Y, He Y, Ohtani T, Jones ME, Shestova O, Xu L, Fang TC, Chiang MY, Intlekofer AM, Blacklow SC, Zhuang Y, Pear WS. Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes & Development. 2009 Jul 15; 23(14):1665-76.

Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, DeJong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL. Anomalous type 17 response to viral infection by CD8⁺ T cells lacking T-bet and eomesodermin. Science. 2008 Jul 18; 321(5887):408-11.

Highlighted in “Editors’ Choice: Immunology – Doubled-Up Decision” by Stephen J. Simpson. Signaling. 2008 Jul 22; 1(29):ec268.
Highlighted in “Research Highlight – T-cell responses: Killer control” by Olive Leavy. Nature Reviews Immunology. 2008 Sep; 8(9):660-1.

Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, Northrop JK, Shen H, Wherry EJ, Reiner SL. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8⁺ T cells. The Journal of Experimental Medicine. 2007 Sep 3; 204(9):2015-21.